Company / EPS (Diluted)
Syndax Pharmaceuticals Inc EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.98
FY2025
5-year range
-$2.98 / $0.46
FY2021-FY2025
Trend
-21.1%
vs FY2024
Sector context
#148 of 204
Health Care
What the data says
At $-2.98, Syndax Pharmaceuticals Inc's eps (diluted) ranks #148 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-1519.27 in FY2017 to $0.46 in FY2023.
Based on SEC 10-K filings.
-2.98 in FY2025.
Declined from $0.46 to $-2.98 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#148 of 204 in Health CareTop 73% of 204This company -$2.98 Sector average -$0.89
▼
-236.3% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 21.1% year-over-year.
- Ranks #148 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.98 | -21.1% |
| FY2024 | -$2.46 | -634.8% |
| FY2023 | $0.46 | +124.6% |
| FY2022 | -$1.87 | -1.6% |
| FY2021 | -$1.84 | +37.0% |
| FY2020 | -$2.92 | -0.7% |
| FY2019 | -$2.90 | +9.9% |
| FY2018 | -$3.22 | +99.8% |
| FY2017 | -$1519.27 | -235.4% |
| FY2016 | -$453.02 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026